Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547642 | 1.00 | FFAR1 (0.41) | FFAR1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL3665499 | 0.90 | FFAR1 (0.43) | FFAR1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL3665498 | 0.90 | FFAR1 (0.43) | FFAR1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL3663394 | 0.88 | FFAR1 (0.42) | FFAR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3870787 | 0.88 | FFAR1 (0.42) | FFAR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3663395 | 0.88 | FFAR1 (0.42) | FFAR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3870789 | 0.88 | FFAR1 (0.42) | FFAR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13318423 | 0.86 | CYP2D6 (0.35) | FFAR1KMT2AMEN1SLC6A3LMNA | |
| SCHEMBL14286051 | 0.86 | CYP2D6 (0.35) | FFAR1KMT2AMEN1SLC6A3LMNA | |
| SCHEMBL13318410 | 0.86 | CYP2D6 (0.35) | FFAR1KMT2AMEN1SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139843-B1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2139843-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | Amgen, Inc (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2061760-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008130514-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | FFAR1 18/4885KMT2A 3040/4885MEN1 3240/4885 |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885KMT2A 1619/4885MEN1 1317/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885KMT2A 1240/4885MEN1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.